CEL-SCI CorporationCVMNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-12.52%
2024-19.18%
2023-11.37%
20229.72%
202129.53%
202040.93%
201934.67%
2018-39.77%
2017-19.35%
2016-7.63%